Who Should Consider This Protocol Patients starting GLP-1 therapy who want to proactively support GI comfort during dose escalation
I went through Telehealth
Allergic reactions are rare
FMS is most commonly present in middle aged females (35-45 years old), but symptoms are often experienced at an earlier age
Visual Format: Side-effect and safety matrix Key Labels: Topical irritation, allergic reaction, formulation sensitivity, wound-care context, injectable route, limited safety data, peptide impurities, immunogenicity risk Suggested Layout: Create a three-column matrix: Topical products, Wound-care study context, and Injectable or compounded preparations. Under each column, list route-specific safety considerations using short, neutral labels
Then use this formula: Dose (mcg) = Volume Drawn (mL) Concentration (mg/mL) 1,000